 Connection
Petter Bjornstad to Natriuresis
This is a "connection" page, showing publications Petter Bjornstad has written about Natriuresis.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.405 |
|
|
|
-
Beernink JM, Jongs N, Mosterd CM, Scholtes RA, Caldwell-McGee A, Casillas D, Driscoll L, Greasley PJ, Karlsson C, Hammarstedt A, Sridhar VS, Muskiet MHA, Laverman GD, Cherney DZI, Bjornstad P, van Raalte DH, Heerspink HJL. Effects of dapagliflozin on sodium excretion, blood pressure and volume status in patients with type 2 diabetes and/or chronic kidney disease: The DAPASALT trial. Diabetes Obes Metab. 2025 08; 27(8):4415-4426.
Score: 0.226
-
León Jiménez D, Cherney DZI, Bjornstad P, Castilla-Guerra L, Miramontes González JP. Antihyperglycemic agents as novel natriuretic therapies in diabetic kidney disease. Am J Physiol Renal Physiol. 2018 11 01; 315(5):F1406-F1415.
Score: 0.141
-
Lytvyn Y, Bjornstad P, Katz A, Singh SK, Godoy LC, Chung LT, Vinovskis CL, Pyle L, Roussel R, Perkins BA, Cherney D. SGLT2 inhibition increases serum copeptin in young adults with type 1 diabetes. Diabetes Metab. 2020 06; 46(3):203-209.
Score: 0.039
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|